Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | F12 | P00748 | 14/20 | 0.35 |
| ▸ | F2 | P00734 | 9/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982872 | 0.75 | NPC1 (0.39) | NPC1RAB9AF12F2ESR1 | |
| SCHEMBL11277506 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL21758675 | 0.70 | NPC1 (0.40) | NPC1RAB9ACNR2F12F2 | |
| SCHEMBL22492312 | 0.70 | F12 (0.39) | NPC1RAB9AF12F2 | |
| SCHEMBL2246755 | 0.68 | ESR1 (0.41) | NPC1RAB9AESR1ESR2LMNA | |
| SCHEMBL22702980 | 0.67 | F12 (0.37) | F12F2ESR1ESR2 | |
| SCHEMBL22702917 | 0.67 | F12 (0.46) | F12F2 | |
| SCHEMBL22702819 | 0.67 | F12 (0.43) | F12F2 | |
| SCHEMBL11281948 | 0.63 | LMNA (0.44) | NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9099759 | 0.63 | CYP2C19 (0.40) | NPC1RAB9ACNR2F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | NPC1 2233/4885RAB9A 3422/4885CNR2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.